NASDAQ:CORT Corcept Therapeutics (CORT) Stock Price, News & Analysis $34.38 +0.28 (+0.82%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$33.66▼$34.6150-Day Range$29.51▼$38.6752-Week Range$20.84▼$39.75Volume554,413 shsAverage Volume1.23 million shsMarket Capitalization$3.58 billionP/E Ratio32.43Dividend YieldN/APrice Target$46.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Corcept Therapeutics alerts: Email Address Corcept Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside35.3% Upside$46.50 Price TargetShort InterestBearish24.00% of Float Sold ShortDividend StrengthN/ASustainability-0.74Upright™ Environmental ScoreNews Sentiment0.66Based on 7 Articles This WeekInsider TradingSelling Shares$1.09 M Sold Last QuarterProj. Earnings Growth42.73%From $1.10 to $1.57 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.83 out of 5 starsMedical Sector29th out of 910 stocksPharmaceutical Preparations Industry10th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingCorcept Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorcept Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Corcept Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted24.00% of the float of Corcept Therapeutics has been sold short.Short Interest Ratio / Days to CoverCorcept Therapeutics has a short interest ratio ("days to cover") of 21.2, which indicates bearish sentiment.Change versus previous monthShort interest in Corcept Therapeutics has recently decreased by 3.01%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCorcept Therapeutics does not currently pay a dividend.Dividend GrowthCorcept Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCorcept Therapeutics has received a 70.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for metabolic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Corcept Therapeutics is -0.74. Previous Next 2.6 News and Social Media Coverage News SentimentCorcept Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Corcept Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for CORT on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,090,844.00 in company stock.Percentage Held by Insiders20.50% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.61% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corcept Therapeutics' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Corcept Therapeutics are expected to grow by 42.73% in the coming year, from $1.10 to $1.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corcept Therapeutics is 32.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Corcept Therapeutics is 32.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 112.46.Price to Book Value per Share RatioCorcept Therapeutics has a P/B Ratio of 6.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Corcept Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Corcept Therapeutics Stock (NASDAQ:CORT)Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Read More CORT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CORT Stock News HeadlinesSeptember 6 at 8:38 AM | insidertrades.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $353,000.00 in StockAugust 29, 2024 | insidertrades.comInsider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells 3,101 Shares of StockSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…September 6 at 9:51 AM | finance.yahoo.comHere's Why Corcept Therapeutics (NASDAQ:CORT) Has Caught The Eye Of InvestorsAugust 31, 2024 | americanbankingnews.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $110,736.71 in StockAugust 29, 2024 | benzinga.comInsider Decision: Gary Charles Robb Offloads $110K Worth Of Corcept Therapeutics StockAugust 28, 2024 | finance.yahoo.comCorcept (CORT) Down 4% Since Last Earnings Report: Can It Rebound?August 26, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT)September 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Corcept Therapeutics on Strong Financials and Promising Drug PipelineAugust 6, 2024 | benzinga.comEngaging In Options Activity, Hazel Hunt Exercises Options Valued At $1.77M In Corcept TherapeuticsJuly 31, 2024 | markets.businessinsider.comBuy Rating Affirmed on Corcept Therapeutics Amid Strong Financials and Promising Clinical OutlookJuly 30, 2024 | seekingalpha.comCorcept Therapeutics: Q2 Gains Overshadowed By Generic Competition And Speculative PipelineJuly 30, 2024 | benzinga.comUnveiling 8 Analyst Insights On Corcept TherapeuticsJuly 30, 2024 | msn.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2024 Earnings Call TranscriptJuly 30, 2024 | gurufocus.comQ2 2024 Corcept Therapeutics Inc Earnings Call TranscriptJuly 30, 2024 | seekingalpha.comCorcept Therapeutics Incorporated (CORT) Q2 2024 Earnings Call TranscriptJuly 24, 2024 | ca.finance.yahoo.comCORT Aug 2024 36.000 callSee More Headlines Receive CORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/29/2024Today9/07/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CORT CUSIP21835210 CIK1088856 Webwww.corcept.com Phone(650) 327-3270Fax650-327-3218Employees300Year Founded1998Price Target and Rating Average Stock Price Target$46.50 High Stock Price Target$65.00 Low Stock Price Target$38.00 Potential Upside/Downside+35.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.06 Trailing P/E Ratio32.43 Forward P/E Ratio31.25 P/E GrowthN/ANet Income$106.14 million Net Margins21.93% Pretax Margin26.30% Return on Equity23.66% Return on Assets19.33% Debt Debt-to-Equity RatioN/A Current Ratio5.57 Quick Ratio5.48 Sales & Book Value Annual Sales$569.61 million Price / Sales6.28 Cash Flow$0.93 per share Price / Cash Flow36.86 Book Value$5.71 per share Price / Book6.02Miscellaneous Outstanding Shares104,110,000Free Float82,767,000Market Cap$3.58 billion OptionableOptionable Beta0.44 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Joseph K. Belanoff M.D. (Age 67)Co-Founder, President, CEO & Director Comp: $2.43MMr. Atabak Mokari (Age 47)CFO & Treasurer Comp: $863.03kMr. Sean Maduck (Age 47)President of Endocrinology Comp: $1.05MDr. William Guyer Pharm.D. (Age 56)Chief Development Officer Comp: $1.03MMr. Gary Charles Robb (Age 61)Chief Business Officer & Secretary Comp: $1.08MMr. Joseph Douglas Lyon (Age 46)Chief Accounting & Technology Officer Dr. Hazel Hunt Ph.D. (Age 64)Chief Scientific Officer Comp: $895.16kMs. Amy FloodChief Human Resources & Communications OfficerMs. Monica Tellado (Age 51)President of Emerging Markets Mr. Roberto W. VieiraPresident of OncologyMore ExecutivesKey CompetitorsAxsome TherapeuticsNASDAQ:AXSMGlobal Blood TherapeuticsNASDAQ:GBTRa PharmaceuticalsNASDAQ:RARXHarmony BiosciencesNASDAQ:HRMYTaro Pharmaceutical IndustriesNYSE:TAROView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 30,466 shares on 9/5/2024Ownership: 0.029%William GuyerSold 10,000 sharesTotal: $353,000.00 ($35.30/share)Clearbridge Investments LLCSold 11,539 shares on 8/27/2024Ownership: 0.548%Gary Charles RobbSold 3,101 sharesTotal: $110,736.71 ($35.71/share)Cetera Investment AdvisersBought 2,244 shares on 8/22/2024Ownership: 0.037%View All Insider TransactionsView All Institutional Transactions CORT Stock Analysis - Frequently Asked Questions How have CORT shares performed this year? Corcept Therapeutics' stock was trading at $32.48 at the start of the year. Since then, CORT shares have increased by 5.8% and is now trading at $34.38. View the best growth stocks for 2024 here. How were Corcept Therapeutics' earnings last quarter? Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its quarterly earnings results on Monday, July, 29th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.09. The company's revenue was up 39.1% compared to the same quarter last year. What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO? 6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Corcept Therapeutics' major shareholders? Corcept Therapeutics' top institutional investors include Renaissance Technologies LLC (6.64%), Dimensional Fund Advisors LP (2.57%), Boston Trust Walden Corp (1.52%) and D. E. Shaw & Co. Inc. (0.91%). Insiders that own company stock include Joseph K Belanoff, Sean Maduck, Hazel Hunt, Gary Charles Robb, David L Mahoney, Joseph Douglas Lyon, William Guyer and Daniel N Swisher, Jr. View institutional ownership trends. How do I buy shares of Corcept Therapeutics? Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Corcept Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), Alibaba Group (BABA) and BlackRock (BLK). This page (NASDAQ:CORT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
